How to win a CPRIT award: lessons from $25M+ in competitive funding

Winning a CPRIT product development award means convincing out-of-state peer reviewers, outside due-diligence contractors, and a state oversight committee that your cancer program is scientifically sound, commercially credible, and good for Texas. Lead with unmet need, present an IND-enabling plan with executable milestones and budget, prove you can fund the required match, and commit to Texas in writing before you apply.

What is CPRIT and where does the money come from?

Texans voted in 2007 to create the Cancer Prevention and Research Institute of Texas and invest $3 billion in cancer research. On November 5, 2019, voters approved a constitutional amendment adding another $3 billion. CPRIT is now a $6 billion, 20-year initiative, the largest state cancer research investment in United States history [1].

The money is borrowed. Article III, Section 67 of the Texas Constitution authorizes up to $6 billion in general obligation bonds, no more than $300 million per year, and requires a grant recipient to have funds equal to one-half of the grant dedicated to the research [6]. Because taxpayers back those bonds, the statute requires a contract, matching funds, and an intellectual property agreement letting the state collect royalties [7].

Which CPRIT product development award fits my company?

CPRIT's Product Development Research Program funds Texas-based companies through four Requests for Applications, all for three-year projects. Only Seed awards are capped, at $3 million; others may request any justified amount from roughly $70 million available per fiscal year. Out-of-state companies may apply but must meaningfully commit to Texas, and CPRIT says not to apply otherwise [2].

Fit between stage and RFA matters as much as the science. The program I led, a first-in-class biologic for a rare pediatric leukemia, had nonclinical efficacy data and a defined IND-enabling plan, placing it in the therapeutics track. CPRIT funded it through a product development award and, later, a supplemental award. A Seed-stage asset submitted to the therapeutics RFA invites fast rejection.

How does CPRIT review a product development application?

The process starts with a preliminary application: a two-page executive summary, up to 16 slides, and one page of aims and budget. The Product Development Review Council decides within three to five weeks whether to invite a full application, and unsuccessful applicants have limited chances to resubmit [2].

A full application goes to a small group of reviewers, each of whom reads 80 to 100 pages and scores it individually before the panel meets to hear the company present and ask questions [8]. Applications that score well go to due diligence by outside contractors covering intellectual property, trial design, regulatory affairs, manufacturability, and marketing. Finally, two-thirds of Oversight Committee members present and voting must approve the award [3].

What do reviewers actually score, and how do I write to it?

The statute lists what Texas wants funded: proposals that could produce medical breakthroughs, are matched with private funds, have a demonstrable economic development benefit to the state, and create high-quality jobs [7]. The RFA adds the programmatic criteria the Review Council applies [3]. My first lesson is to write to both lists in separate, explicit sections; do not expect reviewers to infer the Texas case.

The second lesson is to lead with unmet need. Every reviewer lives and works outside Texas, and at least one patient advocate reviewer sits on each panel [9]. For our biologic, the opening pages described the patients for whom existing therapy fails and what a first-in-class mechanism would change. In my experience advocates read the need statement first and anchor the discussion to it.

The third lesson is that budget and milestones must read like an IND-enabling plan a contract research organization could execute tomorrow. CPRIT disburses funds in tranches, and the next tranche is released only after CPRIT approves a report confirming the prior milestones [4]. A vague milestone becomes an unfunded milestone.

The fourth lesson is that the commercialization plan gets tested, not just read. Due-diligence experts examine intellectual property, regulatory strategy, manufacturability, and market [3], so have licenses executed and a market model that separates addressable from total population. Treat the presentation as an investor pitch; the panel asks about the scientific basis, development and regulatory plans, and business strategy [8]. Let your manufacturing and regulatory leads answer.

What strings come with a CPRIT award?

The Texas location requirement is specific. A grantee must meet four of seven criteria: U.S. headquarters in Texas; CEO residing in Texas; a majority of personnel, including two other C-level employees, in Texas; manufacturing in Texas; at least 90 percent of award funds paid to Texas entities; a Texas clinical trial site; and a Texas medical research collaboration. Compliance is attested annually [4].

The match ratio depends on how much CPRIT has committed to you. Companies with total commitments of $20 million or less contribute $1 for every $2 of CPRIT funds. The award that pushes a company past $20 million carries a dollar-for-dollar match, and past $30 million the match rises to $2 for every $1 [4]. In-kind costs do not count, but costs to relocate operations to Texas do [10].

Revenue sharing is the third string. For therapeutics, Texas receives 3, 4, or 5 percent of revenue, depending on cumulative sales, until it has collected 4X the funds disbursed. Payments begin once product sales exceed $5 million, nothing is owed on pre-revenue milestones, and a 0.5 percent royalty continues after the 4X until exclusivity ends [5]. This is cheaper than preclinical equity, but it stacks a royalty onto every partnering conversation.

What does compliance look like after the award, and is it worth it?

Reporting is continuous. A quarterly Financial Status Report is due within 90 days of each state fiscal quarter, an annual progress report within 60 days of the contract anniversary, tranche reports as milestones complete, and annual matching certification and verification [4]. Rule 703.22 also requires the Authorized Signing Official and one other person to complete compliance training by December 31 [11].

Cash planning matters. CPRIT generally disburses the last 10 percent of funds on a reimbursement basis, and it may hold the final reimbursement until every close-out document is approved [4]. Matching verification requires proof of payment [10], and the statute directs the chief compliance officer to flag grantees who miss reporting or matching obligations for suspension or termination [7]. On our program, one finance lead owned this from day one.

Is it worth it? CPRIT reports more than $852 million approved for 78 companies, invested where private capital is hardest to obtain [8]. In my experience the award validated the program for later investors and funded IND-enabling work without dilution. It also consumed most of a year of leadership attention, and the odds are not generous. Apply when stage, data, and Texas commitment align.

This article is part of the Life Sciences Consulting practice at Hamilton Atlas Group — see the full capability list there.

References

1. Cancer Prevention and Research Institute of Texas. About Us. CPRIT, 2026.
2. Cancer Prevention and Research Institute of Texas. Product Development Research. CPRIT, 2026.
3. Cancer Prevention and Research Institute of Texas. Grants Process. CPRIT, 2026.
4. Cancer Prevention and Research Institute of Texas. Grant Policies and Procedures Guide: A resource for CPRIT grant applicants and grant recipients, June 2026. CPRIT, 2026.
5. Cancer Prevention and Research Institute of Texas. Revenue Sharing. CPRIT, 2026.
6. Texas Legislature. The Texas Constitution, Article 3. Legislative Department, Section 67. Cancer Prevention and Research Institute of Texas; Bonds. Texas Constitution and Statutes, 2019.
7. Texas Legislature. Health and Safety Code, Chapter 102. Cancer Prevention and Research Institute of Texas. Texas Constitution and Statutes, 2013.
8. Cancer Prevention and Research Institute of Texas. Product Development Peer Review. CPRIT, 2026.
9. Cancer Prevention and Research Institute of Texas. Who Reviews My Grant Application? CPRIT, 2026.
10. Texas Administrative Code. 25 Tex. Admin. Code § 703.11 - Requirement to Demonstrate Available Funds for Cancer Research Grants. Legal Information Institute, Cornell Law School, 2025.
11. Cancer Prevention and Research Institute of Texas. Grantee Resources. CPRIT, 2026.